Kainos | Sustainability Performance
Provides IT consulting and digital transformation services for businesses and public sector organizations.
1986
United Kingdom
1,001 - 5,000 employees
Information Technology & Services
$100M - 500M in revenue
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#7180
Overallⓘ#820
in United Kingdomⓘ#260
in Information Technology & ServicesⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Carbon certificatesGovernance
TargetsFinancial Data
Business performanceCapital & innovationAnalyst projections
Controversy level
- The company, as the original maker of the heartburn drug Zantac (ranitidine), is a defendant in extensive U.S. productliability litigation alleging the drug could degrade into the probable human carcinogen NDMA (Nnitrosodimethylamine) and cause cancer, and that the company failed to warn patients; the company has reached settlements with numerous plaintiffs (including a roughly $2.2 billion settlement framework in 2024 covering the bulk of U.S. statecourt claims) while not admitting liability.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.